Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
08 août 2022 07h05 HE | uniQure Inc.
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of...
Freeline_Logo_Red_RGB.jpg
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 août 2022 16h01 HE | Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
22157.jpg
Asia Pacific Cancer Gene Therapy Market Report 2022: Featuring Key Players Novartis, GlaxoSmithKline, Amgen, Bristol Myers Squibb, Gilead Sciences,. Adaptimmune, Genelux & Sarepta Therapeutics,
04 août 2022 04h53 HE | Research and Markets
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "Asia Pacific Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic...
ocugen_4C_LOGO (002).png
Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
29 juil. 2022 07h30 HE | Ocugen
MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and...
AGC Biologics Supports Altheia Science’s Gene Therapy Programs
28 juil. 2022 08h00 HE | AGC Biologics
SEATTLE, MILAN, July 28, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with...
Global Viral Vector & Plasmid DNA Manufacturing Market Report to 2027 - Featuring ABL, Biovian and GE Healthcare Among Others
28 juil. 2022 06h13 HE | Research and Markets
Dublin, July 28, 2022 (GLOBE NEWSWIRE) -- The "Viral Vector & Plasmid DNA Manufacturing Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's...
Roots-Analysis-Logo.png
The gene therapy market is projected to be worth USD 17.3 billion in 2035, growing at a CAGR of 18%, during the period 2022-2035, claims Roots Analysis
27 juil. 2022 10h00 HE | Roots Analysis
London, July 27, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Gene Therapy Market” report to its list of offerings. Post the emergence of blockbuster gene therapies, such...
Freeline_Logo_Red_RGB.jpg
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
21 juil. 2022 07h00 HE | Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
FronteraTherapeutics_Logo_300dpi.jpg
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
19 juil. 2022 08h00 HE | Frontera Therapeutics
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may...
Adverum_Primary_Medium.png
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
15 juil. 2022 08h32 HE | Adverum Biotechnologies, Inc.
- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years - Mean best-corrected visual acuity...